Integrating therapies for surgical adult soft tissue sarcoma patients

Milgrom, Daniel P.; Sehdev, Amikar; Kays, Joshua K.; Koniaris, Leonidas G.

doi:10.21037/tgh.2018.10.12

Cited by 4 publications

(3 citation statements)

References 80 publications

(107 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This strategy has proven to improve outcomes in soft tissue sarcomas (49)(50)(51)(52). For a more in depth overview on sarcoma management please see the article by Milgrom et al in this special issue (53).…”

Section: A B C D Treatmentmentioning

confidence: 99%

Solitary fibrous tumor

Davanzo¹,

Emerson²,

Lisy³

et al. 2018

Transl. Gastroenterol. Hepatol

Self Cite

141

171

View full text Add to dashboard Cite

Solitary fibrous tumor (SFT) is a rare tumor of mesenchymal origin that account for less than 2% of all soft tissue masses. Initially identified in the pleura, SFT has been identified in multiple anatomic locations and can arise anywhere in the body. The varying histologic features along with non-specific means of identification have led SFT to be associated with several different names. Over the last several decades, sustained advances through research and technology have led to more reliable methods for differentiating this distinct soft tissue tumor. Advances specifically in immunohistochemistry and molecular diagnostics have identified CD34 as the most consistent marker in SFT, however even this lacks specificity to conclusively narrow down the broad differential for exact identification. More recently the discovery of the NAB2-STAT6 fusion gene has led to more precise diagnosis of SFT. Like many other soft tissue tumors, surgical management is the mainstay of treatment for SFT with emphasis on obtaining tumor-negative margins. Radiation therapy and chemotherapy regimens have not demonstrated global effectiveness, and thus no standardized treatments have been identified. Given the rarity of SFT and current supportive evidence for therapies, management should be focused on tumor extirpation. Nonetheless, individualized therapy, determined within a multidisciplinary setting should be considered.

show abstract

Section: A B C D Treatmentmentioning

confidence: 99%

Solitary fibrous tumor

Davanzo¹,

Emerson²,

Lisy³

et al. 2018

Transl. Gastroenterol. Hepatol

Self Cite

141

171

View full text Add to dashboard Cite

show abstract

“…Retroperitoneal sarcomas carry the lowest cure and survival rates by location. This is due to their increased size, late diagnosis, and inability to obtain complete extirpation, due to their close proximity to multiple essential organs and major blood vessels [ 8 , 9 ]. The optimal treatment involves obtaining a margin-negative resection.…”

Section: Discussionmentioning

confidence: 99%

Bilateral Renal Auto-Transplantation for Retroperitoneal Sarcomas: Is It Underutilized?

Robinson,

Milgrom,

Nagaraju

et al. 2023

Current Oncology

Self Cite

View full text Add to dashboard Cite

Sarcomas are a rare tumor of mesenchymal origin. The liposarcoma is the most common sarcoma of the retroperitoneum. Liposarcomas are typically low grade, and present at an advanced stage and a large size. We report a case of a large retroperitoneal liposarcoma, approximately 50 kg, encasing both kidneys, which was managed via a two-stage resection and staged renal auto-transplantation into the intra-peritoneal pelvis. The patient maintained normal renal function throughout, and remains disease free two years post-resection. Renal auto-transplantation with pelvic placement may facilitate improved margin-free resection. Renal relocation may allow the use of curative-intent ablative therapies such as radiofrequency ablation and radiation in cases of retroperitoneal recurrence.

show abstract

“…Quiroz and coworkers examine the evolving management of pediatric gastrointestinal stromal tumors (GIST) that increasingly must be recognized as a different disease from that arising in older adults (5,6). Milgrom and coworkers similarly provide a balanced review of the overall management strategies for adult sarcoma patients targeted for students, residents, or fellows (7). Similarly, Gbolanhan and O'Neil have provided a very comprehensive review of current adjuvant, and evolving biologic therapies for patients with colon cancer (8).…”

mentioning

confidence: 99%